CDEK
← All drugs Report issue

ranpirnase

Trade name: Onconase

Animal productexperimental

Ranpirnase is a ribonuclease enzyme found in the oocytes of the Northern Leopard Frog. Ranpirnase is a member of the pancreatic ribonuclease protein superfamily and degrades RNA substrates with a sequence preference for uracil and guanine nucleotides. Along with amphinase, another leopard frog ribonuclease, Ranpirnase has been studied as a potential cancer and antiviral treatment due to its unusual mechanism of cytotoxicity tested against transformed cells and antiviral activity. — Wikipedia

Clinical trial activity

4 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0

Earliest trial started May 1, 1997 (NCT00003034)

Timeline

1990s

  1. Jan 1, 1997

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • tRNAHYDROLYTIC ENZYME

    tRNA hydrolytic enzyme

    Ranpirnase binds to the cell surface and uses the energy-dependent endocytic process to penetrate into the cell, routed through the Golgi apparatus to the cytosol, where it preferentially degrades tRNA (but not ribosmal and mRNA) by catalyzing the cleavage of the P-O5¿ bond of RNA on the 3¿ side of pyrimidine nucleosides. This RNA degradation leads to inhibition of protein synthesis and, ultimately, to the cytostatic and cytotoxic activity of ranpirnase.

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • onconase
  • onconase
  • p-30 protein
  • p-30 protein, rana pipiens
  • p30 protein, rana pipiens
  • pannon
  • ranpirnase
  • ranpirnase
  • ranpirnase
  • ranpirnase

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03856645Phase 2Feb 11, 2019Okogen, Inc.
NCT02535104Phase 1/Phase 2 (Phase 2)Feb 1, 2016Tamir Biotechnology, Inc.
NCT01184287Phase 2Aug 17, 2010Tamir Biotechnology, Inc.
NCT00003034Phase 3May 1, 1997Tamir Biotechnology, Inc.
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tamir Biotechnology, Inc.For profit3321997
Okogen, Inc.For profit1112019
2 organizations
Page 1 / 1